Sei Investments Co. Has $43.62 Million Stock Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Sei Investments Co. boosted its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 25.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 148,229 shares of the biotechnology company’s stock after purchasing an additional 30,291 shares during the period. Sei Investments Co. owned 0.20% of Axon Enterprise worth $43,615,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AXON. ICA Group Wealth Management LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at about $26,000. Blue Trust Inc. increased its stake in shares of Axon Enterprise by 987.5% during the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 79 shares during the last quarter. Trivant Custom Portfolio Group LLC bought a new position in shares of Axon Enterprise during the 1st quarter valued at $31,000. First PREMIER Bank acquired a new stake in shares of Axon Enterprise in the 1st quarter valued at $33,000. Finally, Rise Advisors LLC boosted its holdings in Axon Enterprise by 49.0% in the first quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $393.29 on Monday. The stock has a market cap of $29.68 billion, a P/E ratio of 115.00, a PEG ratio of 10.34 and a beta of 0.94. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a twelve month low of $189.12 and a twelve month high of $393.58. The company’s 50-day simple moving average is $348.04 and its 200 day simple moving average is $317.24.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. During the same quarter last year, the company earned $0.80 EPS. Axon Enterprise’s revenue was up 34.5% on a year-over-year basis. As a group, research analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Barclays raised their target price on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Northland Securities upped their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Bank of America began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 price objective on shares of Axon Enterprise in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $365.38.

Insider Transactions at Axon Enterprise

In related news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $380.99, for a total transaction of $380,990.00. Following the completion of the transaction, the director now directly owns 27,259 shares of the company’s stock, valued at approximately $10,385,406.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the sale, the director now owns 7,379 shares in the company, valued at $2,752,588.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $380.99, for a total value of $380,990.00. Following the completion of the transaction, the director now directly owns 27,259 shares of the company’s stock, valued at $10,385,406.41. The disclosure for this sale can be found here. In the last quarter, insiders have sold 317,981 shares of company stock valued at $115,662,734. 6.10% of the stock is owned by insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.